Publikationen, an denen er mitarbeitet Antonio Rivero Román (28)

2021

  1. Cd46 genetic variability and hiv-1 infection susceptibility

    Cells, Vol. 10, Núm. 11

2016

  1. Common haplotypes in CD209 promoter and susceptibility to HIV-1 infection in intravenous drug users

    Infection, Genetics and Evolution, Vol. 45, pp. 20-25

2015

  1. Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection

    Genes and Immunity, Vol. 16, Núm. 2, pp. 134-141

  2. IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection

    AIDS

  3. Longitudinal evaluation of hepatitis C viral persistence in HIV-infected patients with spontaneous hepatitis C clearance

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 11, pp. 2171-2175

2014

  1. A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers

    Liver International, Vol. 34, Núm. 4, pp. 558-566

  2. Association of low-density lipoprotein receptor genotypes with hepatitis C viral load

    Genes and Immunity, Vol. 15, Núm. 1, pp. 16-24

  3. IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians

    PLoS ONE, Vol. 9, Núm. 4

2013

  1. A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients

    Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 4, pp. 915-921

  2. Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV

    Infection, Vol. 41, Núm. 1, pp. 21-26

  3. Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 32, Núm. 11, pp. 1427-1435

  4. Natural Killer KIR3DS1 Is Closely Associated with HCV Viral Clearance and Sustained Virological Response in HIV/HCV Patients

    PLoS ONE, Vol. 8, Núm. 4

  5. Pegylated interferon plus ribavirin is suboptimal inIL28B CC carriers without rapid response

    Journal of Infection, Vol. 67, Núm. 1, pp. 59-64

  6. Short communication: Atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C

    AIDS Research and Human Retroviruses, Vol. 29, Núm. 2, pp. 223-225

  7. The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylatedinterferon/ ribavirin treatment varies according to hepatitis C virus-1 subtype

    AIDS, Vol. 27, Núm. 12, pp. 1941-1947

  8. Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection

    AIDS, Vol. 27, Núm. 17, pp. 2715-2724

2012

  1. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 1, pp. 202-205

  2. Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients

    PLoS ONE, Vol. 7, Núm. 11

  3. Differences in virological response to peginterferon-a plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b

    Journal of Acquired Immune Deficiency Syndromes, Vol. 60, Núm. 2, pp. 117-123

  4. LDLr genotype modifies the impact of IL28B on HCV viral kinetics after the first weeks of treatment with PEG-IFN/RBV in HIV/HCV patients

    AIDS, Vol. 26, Núm. 8, pp. 1009-1015